Monte Rosa Therapeutics (GLUE) Net Margin (2024 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly Net Margin came in at 1036.07% in Q1 2026, down 109127.0% year-on-year from N/an in Q1 2025, and up 2.29% quarter-over-quarter from 1060.37% in Q4 2025.
Monte Rosa Therapeutics (GLUE) Net Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Net Margin history runs 3 years deep, the most recent figure standing at 1036.07% for Q1 2026.
- On a quarterly basis, Net Margin fell 109127.0% year-over-year to 1036.07% in Q1 2026; TTM through Mar 2026 was 2637.58%, a 265228.0% decrease from a year earlier, with the FY2025 full-year figure at 17.77%, up 5549.0% from the prior year.
- Net Margin improved to 1036.07% in Q1 2026 per GLUE's latest filing, from 1060.37% in the prior quarter.
- Across five years, Net Margin topped out at 55.2% in Q1 2025 and bottomed at 3006.11% in Q1 2024.
- The 3-year median for Net Margin is 258.89% (2024), against an average of 658.66%.
- Biggest YoY gain for Net Margin was 306131 bps in 2025; the steepest drop was 111105 bps in 2025.
- Year by year, Net Margin stood at 50.68% in 2024, then slumped by 2192 bps to 1060.37% in 2025, then gained by 2 bps to 1036.07% in 2026.
- Per Business Quant, the three latest GLUE Net Margin figures stand at 1036.07% (Q1 2026), 1060.37% (Q4 2025), and 18.05% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | -1,036.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,036.07% |
| Dec 31, 2025 | -1,060.37% |
| Sep 30, 2025 | -18.05% |
| Jun 30, 2025 | -8.77% |
| Mar 31, 2025 | 55.20% |
| Dec 31, 2024 | 50.68% |
| Sep 30, 2024 | -258.89% |
| Jun 30, 2024 | -645.58% |
| Mar 31, 2024 | -3,006.11% |